Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women.

Publication date: Jul 13, 2023

This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women. 18-45-year-old pregnant women with no history of COVID-19 infection or vaccination and a gestational age of ≥12 weeks were randomized 1:1:1 into three two-dose primary series scheduled 4 weeks apart: BNT162b2-BNT162b2 (Group 1), ChAdOx1-BNT162b2 (Group 2), and CoronaVac-BNT162b2 (Group 3). Serum antibody responses, maternal and cord blood antibody levels at delivery, and adverse events (AEs) following vaccination until delivery were assessed. The 124 enrolled participants had a median age of 31 (interquartile range [IQR] 26. 0-35. 5) years and gestational age of 23. 5 (IQR 18. 0-30. 0) weeks. No significant difference in anti-receptor binding domain (RBD) IgG were observed across arms at 2 weeks after the second dose. Neutralizing antibody geometric mean titers against the ancestral Wuhan strain were highest in Group 3 (258. 22, 95% CI [187. 53, 355. 56]), followed by Groups 1 (187. 47, 95% CI [135. 15, 260. 03]) and 2 (166. 63, 95% CI [124. 60, 222. 84]). Cord blood anti-RBD IgG was correlated with, and equal to or higher than, maternal levels at delivery (r = 0. 719, P 

Concepts Keywords
12weeks BNT162b2
Bnt162b2 ChAdOx1
Thai CoronaVac
Vaccination Heterologous schedules
Women Homologous schedules


Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO pregnant women
disease IDO history
disease MESH infection
disease VO dose
disease VO CoronaVac
drug DRUGBANK Aspartame

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *